Woodline Partners’s Vor Biopharma VOR Stock Holding History

Woodline Partners’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-27,363	Closed	-$1.33M	–	1123
2025 Q3	$1.33M	Buy	+27,363	New	+$1.1M	0.01%	778
2024 Q2	–	Sell	-55,556	Closed	-$2.63M	–	680
2024 Q1	$2.63M	Hold	55,556	–	–	0.02%	412
2023 Q4	$2.5M	Hold	55,556	–	–	0.03%	367
2023 Q3	$2.36M	Hold	55,556	–	–	0.03%	384
2023 Q2	$3.43M	Hold	55,556	–	–	0.04%	350
2023 Q1	$5.98M	Hold	55,556	–	–	0.08%	265
2022 Q4	$7.39M	Hold	55,556	–	–	0.1%	259
2022 Q3	$4.42M	Hold	55,556	–	–	0.06%	321
2022 Q2	$5.52M	Hold	55,556	–	–	0.09%	246
2022 Q1	$6.71M	Hold	55,556	–	–	0.11%	216
2021 Q4	$12.9M	Hold	55,556	–	–	0.18%	154
2021 Q3	$17.4M	Sell	55,556 -1,769	-3%	-$526K	0.28%	100
2021 Q2	$21.4M	Sell	57,325 -338	-0.6%	-$167K	0.4%	64
2021 Q1	$49.7M	Buy	+57,663	New	+$48.8M	1.1%	14

Other funds holding VOR

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

NCM

NEXTBio Capital Management Menlo Park, California $215M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Woodline Partners's VOR Position: Q4 2025 in Review

Woodline Partners sold out of Vor Biopharma (VOR) in Q4 2025, closing a stake of 27,363 shares — an estimated $1.33M sold.

Woodline Partners first reported a position in VOR in Q1 2021 and held it in 14 quarters. The position peaked at $49.7M in Q1 2021. 55 funds tracked by Wall St. Rank hold VOR as of Q4 2025.

Woodline Partners reported no remaining Vor Biopharma position as of Q4 2025 after selling out during the quarter.
Woodline Partners sold 27,363 Vor Biopharma shares in Q4 2025, an estimated $1.33M.
Woodline Partners first reported a position in Vor Biopharma in Q1 2021 and held it in 14 quarters.
Woodline Partners's Vor Biopharma position peaked at $49.7M in Q1 2021.
55 funds tracked by Wall St. Rank held Vor Biopharma as of Q4 2025.

Based on Woodline Partners's 13F filing for Q4 2025, filed 17 Feb 2026.